Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;61(8):923-929.
doi: 10.1111/ijd.16222. Epub 2022 Apr 10.

Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

Affiliations
Review

Stevens-Johnson syndrome precipitated by Moderna Inc. COVID-19 vaccine: a case-based review of literature comparing vaccine and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

Jessica J Padniewski et al. Int J Dermatol. 2022 Aug.

Abstract

The Moderna COVID-19 vaccination was approved for use in the United States in December of 20201 and since that time massive public health efforts have been made to vaccinate patients against the COVID-19 infection. Adverse reactions from the vaccination are well-reported and include both local skin reactions, such as pain, swelling, and erythema at the injection site, as well as systemic reactions including fever, malaise, headache, muscle aches, drowsiness, nausea, and vomiting. While severe serious cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), remain rare; two cases of SJS/TEN related to COVID-19 vaccination have been reported. We herein review the two previously reported cases of SJS/TEN and report the first case of SJS precipitated by the Moderna Inc., MRNA 1273 COVID-19 vaccination in the United States. Although we review potential adverse reactions to vaccination, the benefits of COVID-19 vaccination outweigh the risks based on current data. Cases should be reported to the Vaccine Adverse Event Reporting System (https://vaers.hhs.gov/) to help public health officials recognize and track these severe but rare adverse events.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1
Figure 1
(a) Clinical photograph of patient's face showing dusky, pink‐purple plaques on her eyelids and cheeks with nasal and oral mucosal sloughing. (b) Clinical photograph of patient's face revealing nasal and oral mucosal sloughing
Figure 2
Figure 2
(a) Clinical photograph of patient's trunk showing small, dusky, purple papules coalescing into plaques. (b) Clinical photograph of patient's arms showing small, dusky, purple papules coalescing into plaques across arms
Figure 3
Figure 3
(a) Clinical photographs of palms showing violaceous annular lesions. (b) Clinical photographs of soles showing violaceous annular lesions
Figure 4
Figure 4
Histopathologic examination of right forearm skin biopsy. (a) Histopathologic slide from right forearm showing separation of the epidermis and dermis with mild chronic inflammation composed predominately of lymphocytes (hematoxylin and eosin stain x20). (b) Histopathologic slide from right forearm (hematoxylin and eosin, x100). (c) Histopathologic slide from right forearm (hematoxylin and eosin, x200). (b, c) reveal overlying confluent and full‐thickness necrosis of epidermis associated with mild perivascular infiltrate of lymphocytes and a basket weave‐type stratum corneum.

Similar articles

Cited by

References

    1. Fact sheet for recipients and caregivers emergency use authorization (eua) of the moderna covid‐19 vaccine to prevent coronavirus disease 2019 (covid‐19) in individuals 18 years of age and older . https://www.fda.gov/media/144638/download#page=2a
    1. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID‐19 vaccination: a registry‐based study of 414 cases. J Am Acad Dermatol 2021; 85(1): 46–55. 10.1016/j.jaad.2021.03.092 - DOI - PMC - PubMed
    1. Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA‐1273 vaccine against SARS‐CoV‐2. N Engl J Med 2021; 384(13): 1273–1277. 10.1056/NEJMc2102131. Epub 2021 Mar 3. PMID: 33657292; PMCID: PMC7944952. - DOI - PMC - PubMed
    1. Gambichler T, Scholl L, Ocker L, Stranzenbach R. Prompt onset of erythema multiforme following the first BNT162b2 SARS‐CoV‐2 vaccination. J Eur Acad Dermatol Venereol 2021; 35(7): 415–416. 10.1111/jdv.17225 - DOI - PMC - PubMed
    1. Kong J, Cuevas‐Castillo F, Nassar M, et al. Bullous drug eruption after second dose of mRNA‐1273 (Moderna) COVID‐19 vaccine: Case report. J Infect Public Health 2021; 14(10): 1392–1394. 10.1016/j.jiph.2021.06.021 - DOI - PMC - PubMed

Substances